Возможности применения апиксабана на разных этапах ведения больных с тромбоэмболией легочной артерии

В статье обсуждаются проблемы антикоагулянтной терапии при тромбоэмболии легочной артерии. Четко обозначены основные преимущества и предпочтительное использование прямых селективных пероральных антикоагулянтов, представленных ингибитором тромбина дабигатраном и группой ингибиторов фактора Xa в составе апиксабана, эдоксабана и ривароксабана. Основное внимание уделено апиксабану, доказательная база которого позволяет рассматривать его как приоритетный антикоагулянт, использование которого уместно у большинства больных с тромбоэмболией легочной артерии с первых часов болезни и до многолетней вторичной профилактики.

1. Cohen A.T., Agnelli G., Anderson F.A., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756-764.

2. Klok F.A., Zondag W., van Kralingen K.W., et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med. 2010; 181: 501–506.

3. Tagalakis V., Patenaude V., Kahn S.R., Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126(832): e13–e21.

4. Strickers H. Chronic thromboembolic pulmonary hypertension – a diagnostic and therapeutic update. VASA. 2016; 45: 195–199.

5. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: Suppl: e419S-e494S.

6. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., Cushman M., Moll S., Kessler C.M., Elliott C.G., Paulson R., Wong T., Bauer K.A., Schwartz B.A., Miletich J.P., Bounameaux H., Glynn R.J., for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 348: 1425-1434.

7. Kearon C., Ginsberg J.S., Kovacs M.J., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 349: 631-639.

8. Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406–1415.

9. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med., 2009; 361: 2342-2352.

10. Schulman S., Kakkar A.K., Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764–772.

11. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799–808.

12. Bauersachs R., Berkowitz S.D., Brenner B., et al.. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;.363: 2499–2510.

13. Buller H.R., Prins M.H., Lensin A.W. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287–1297.

14. Prins M.H., Lensing A.W., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11: 21.

15. van der Hulle T., Kooiman J., den Exter P.L., Dekkers O.M., Klok F.A., Huisman M.V. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014; 12: 320–328.

16. Raskob G.E., Gallus A.S., Sanders P., Thompson J.R., Agnelli G., Buller H.R., Cohen A.T., Ramacciotti E., Weitz J.I. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial Thromb Haemost. 2015 Dec 10; 115(4).

17. Schulman S., Kearon C., Kakkar A.K., et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709-718.

18. Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., Lensing A.W., Misselwitz F., Prins M.H., Raskob G.E., Segers A., Verhamme P., Wells P., Agnelli G., Bounameaux H., Cohen A., Davidson B.L., Piovella F., Schellong S. for the EINSTEIN investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010; 363(26): 2499-2510.

19. Agnelli G., Buller H.R., Cohen A., et al; AMPLIFYEXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.

20. Weitz J.I., Lensing A.W., Prins M.H., et al; for the EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017. doi: 10.1056/NEJMoa1700518.